Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma


Autoria(s): Obermair, Andreas; Mileshkin, Linda; Merollini, Katharina; Kondalsamy-Chennakesavan, Srinivas; Cheuk, Robyn; Vasey, Paul; Wyld, David; Goh, Jeffrey; Nicklin, James L.; Perrin, Lewis C.; Sykes, Peter; Janda, Monika
Data(s)

2010

Resumo

Objective Uterine Papillary Serous Carcinoma (UPSC) is uncommon and accounts for less than 5% of all uterine cancers. Therefore the majority of evidence about the benefits of adjuvant treatment comes from retrospective case series. We conducted a prospective multi-centre non-randomized phase 2 clinical trial using four cycles of adjuvant paclitaxel plus carboplatin chemotherapy followed by pelvic radiotherapy, in order to evaluate the tolerability and safety of this approach. Methods This trial enrolled patients with newly diagnosed, previously untreated patients with stage 1b-4 (FIGO-1988) UPSC with a papillary serous component of at least 30%. Paclitaxel (175 mg/m2) and carboplatin (AUC 6) were administered on day 1 of each 3-week cycle for 4 cycles. Chemotherapy was followed by external beam radiotherapy to the whole pelvis (50.4 Gy over 5.5 weeks). Completion and toxicity of treatment (Common Toxicity Criteria, CTC) and quality of life measures were the primary outcome indicators. Results Twenty-nine of 31 patients completed treatment as planned. Dose reduction was needed in 9 patients (29%), treatment delay in 7 (23%), and treatment cessation in 2 patients (6.5%). Hematologic toxicity, grade 3 or 4 occurred in 19% (6/31) of patients. Patients' self-reported quality of life remained stable throughout treatment. Thirteen of the 29 patients with stages 1–3 disease (44.8%) recurred (average follow up 28.1 months, range 8–60 months). Conclusion This multimodal treatment is feasible, safe and tolerated reasonably well and would be suitable for use in multi-institutional prospective randomized clinical trials incorporating novel therapies in patients with UPSC.

Formato

application/pdf

Identificador

http://eprints.qut.edu.au/39535/

Publicador

Elsevier

Relação

http://eprints.qut.edu.au/39535/1/c39535.pdf

DOI:10.1016/j.ygyno.2010.10.039

Obermair, Andreas, Mileshkin, Linda, Merollini, Katharina, Kondalsamy-Chennakesavan, Srinivas, Cheuk, Robyn, Vasey, Paul, Wyld, David, Goh, Jeffrey, Nicklin, James L., Perrin, Lewis C., Sykes, Peter, & Janda, Monika (2010) Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. Gynecologic Oncology, 120(2), pp. 179-184.

Direitos

Copyright 2010 Elsevier Inc.

Fonte

Faculty of Health; Institute of Health and Biomedical Innovation; School of Public Health & Social Work

Palavras-Chave #111700 PUBLIC HEALTH AND HEALTH SERVICES #Uterine Papillary Serous Carcinoma #Carboplatin #Paclitaxel #Radiotherapy #Feasibility
Tipo

Journal Article